Heart transplant patients get new weapon against hidden artery damage
NCT ID NCT03537742
First seen Apr 19, 2026 · Last updated May 27, 2026 · Updated 5 times
Summary
This study tested the drug alirocumab in 114 heart transplant recipients to see if it could slow or prevent a common complication called cardiac allograft vasculopathy (CAV), where the heart's blood vessels narrow. Participants received the drug soon after transplant, and researchers measured changes in plaque buildup in the coronary arteries using ultrasound. The goal was to see if lowering cholesterol with this drug could protect the new heart from vessel damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.